- Home
- BLRX
BLRX
BioLineRx Ltd.
as 04-23-2025 4:00pm EST
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 10.3M | IPO Year: | 2011 |
| Target Price: | $26.00 | AVG Volume (30 days): | 30.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $35.60 | Next Earning Date: | 05-27-2025 |
| Revenue: | $28,940,000 | Revenue Growth: | 502.92% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioLineRx Ltd. News
BLRX Breaking Stock News: Dive into BLRX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
21 days ago
BLRX: 2024 Financial Results
GuruFocus.com
22 days ago
BioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ...
PR Newswire
24 days ago
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
PR Newswire
a month ago
BioLineRx to Report 2024 Annual Results on March 31, 2025
Zacks Small Cap Research
2 months ago
BLRX: Aphexda Transition Progressing
PR Newswire
3 months ago
BioLineRx Issues Letter to Shareholders
MT Newswires
3 months ago
BioLineRx Changes Ratio of ADSs to Ordinary Shares
PR Newswire
3 months ago
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
Compare BLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLRX BioLineRx Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.